Galectin Therapeutics (GALT) AI Stock Analysis

• Market Cap: $158.86M
• Dividend Yield: N/A
• Average Volume (3M): 909.83K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: N/A
• EPS Growth: -1.60%
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.15
• Shares Outstanding: 63,291,584
• 10 Day Avg. Volume: 2,413,141
• 30 Day Avg. Volume: 909,834
• PEG Ratio: -0.07
• Price to Book (P/B): -1.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.16
• Enterprise Value/Market Cap: 0.56
• Enterprise Value/Revenue: 552.42
• Enterprise Value/Gross Profit: -9.82K
• Enterprise Value/Ebitda: -0.58
• 1Y Price Target: $6.00
• Price Target Upside: 155.32% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 35 Underperform
• Price Target: ―

Galectin Therapeutics is a high-risk investment due to its challenging financial position, characterized by no revenues and high financial losses. However, the company's progress in clinical trials and potential partnerships offer a positive long-term outlook. Technical indicators suggest mixed short-term momentum, while traditional valuation metrics are less applicable due to ongoing losses and the absence of dividends.

Positive Factors

Clinical development

Belapectin is the only therapy in development for MASH cirrhosis and portal hypertension, addressing a patient population with no approved therapies.

Clinical outcomes

Belapectin 2 mg/kg exhibited a significant positive effect on HVPG in patients with MASH cirrhosis without varices at baseline, indicating its clinical potential.

Negative Factors

Clinical trial challenges

Belapectin's clinical journey has been bumpy, with neither dose achieving the primary endpoint in early trials.

Investor sentiment

Investor sentiment on GALT is now rather poor, given this is the second Phase 2b trial to miss its primary endpoint.

Galectin Therapeutics Business Overview & Revenue Model

Company Description

Galectin Therapeutics Inc. is a biotechnology company focused on developing innovative therapies to improve the lives of patients with chronic liver diseases and cancer. The company operates in the biotechnology and pharmaceutical sectors, with a core emphasis on discovering and developing drugs targeting galectin proteins, which are critical in numerous disease processes. Galectin Therapeutics aims to leverage its proprietary technology to create novel treatments, primarily targeting fibrosis and cancer.

How the Company Makes Money

Galectin Therapeutics primarily makes money through research and development collaborations, licensing agreements, and milestone payments related to its drug candidates. The company partners with larger pharmaceutical firms to advance the development and commercialization of its therapies, receiving payments for achieving specific research and development milestones. Additionally, Galectin Therapeutics may earn revenue through licensing its proprietary technology and intellectual property to other companies, which can include upfront payments, royalties, and other financial incentives contingent upon the successful commercialization of their drug candidates.

Galectin Therapeutics Financial Statement Overview

Summary

Galectin Therapeutics exhibits the financial profile of an early-stage biotechnology company with no revenue production and increasing financial losses. The balance sheet is strained, marked by high debt and negative equity, suggesting potential financial risk. Cash flow trends demonstrate reliance on external financing to sustain operations, typical for firms focused on R&D in the biotech sector. This financial position underscores the importance of successful future product development and commercialization.

Income Statement

Galectin Therapeutics has consistently reported zero revenue over the last several years, indicating a lack of commercialized products. The net income has been negative, with losses growing from $13.38 million in 2019 to $47.05 million in 2024. This trend reflects increasing operating costs without offsetting revenue, a common challenge for biotechnology firms in the R&D phase.

Balance Sheet

The company has negative stockholders' equity, which worsened from $45.60 million positive in 2019 to $103.07 million negative in 2024, indicating high leverage and financial instability. The total debt has increased significantly, while assets remain low, reflecting potential liquidity issues and reliance on debt financing.

Cash Flow

Operating cash flow has been negative, indicating cash burn typical for pre-revenue biotech firms. However, the company has managed to secure financing cash flow intermittently, indicating some success in raising funds to support operations. Despite this, free cash flow remains negative, highlighting ongoing financial challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-9.00K	0.00	-33.00K	-32.00K	-41.00K	-36.00K
EBITDA	-31.04M	-41.47M	-38.24M	-38.27M	-30.00M	-23.34M
Net Income	-45.19M	-47.05M	-41.07M	-38.78M	-30.53M	-23.46M
Balance Sheet
Total Assets	9.53M	17.50M	28.20M	21.29M	41.83M	29.60M
Cash, Cash Equivalents and Short-Term Investments	7.43M	15.12M	25.66M	18.59M	39.65M	27.14M
Total Debt	107.92M	106.25M	71.81M	39.87M	29.06M	44.00K
Total Liabilities	121.79M	120.56M	88.44M	53.48M	39.21M	5.41M
Stockholders Equity	-113.98M	-103.07M	-60.24M	-32.19M	2.62M	24.19M
Cash Flow
Free Cash Flow	-37.35M	-41.77M	-32.97M	-31.06M	-24.31M	-20.60M
Operating Cash Flow	-37.35M	-41.77M	-32.97M	-31.06M	-24.31M	-20.60M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	21.23M	31.23M	40.03M	10.00M	36.81M	263.00K

Galectin Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GALT, the sentiment is Positive. The current price of 2.35 is above the 20-day moving average (MA) of 1.75, above the 50-day MA of 1.50, and above the 200-day MA of 1.85, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 61.39 is Neutral, neither overbought nor oversold. The STOCH value of 42.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GALT.

Galectin Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRVO	52 Neutral	$59.35M	―	-93.42%	―	142.42%	53.38%
Sector *	51 Neutral	$7.41B	0.32	-61.11%	2.34%	16.99%	1.69%
ANIX	49 Neutral	$106.62M	―	-61.14%	―	-100.00%	-24.28%
PLRX	37 Underperform	$84.71M	―	-63.22%	―	-100.00%	-26.44%
GALT	35 Underperform	$158.86M	―	48.74%	―	―	-1.60%
HLVX	35 Underperform	$95.27M	―	-54.64%	―	―	1.27%
VOR	33 Underperform	$69.28M	―	-125.43%	―	―	2.98%

Galectin Therapeutics Corporate Events

Galectin Therapeutics Updates Investors on Clinical Trials

On March 5, 2025, Galectin Therapeutics announced the availability of its updated corporate presentation on its website, intended for use in investor and analyst meetings. The presentation highlights the company’s focus on advancing its clinical trials for Belapectin, which has shown promising results in reducing new varices in MASH cirrhosis patients and in cancer treatment when combined with checkpoint inhibitors. The company is also exploring potential partnerships and funding opportunities to support its ongoing research and development efforts.